Overview

Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

To test the hypothesis that PPAR-gamma agonist, rosiglitazone, induces carotid plaque regression in diabetic ESRD patients on maintenance PD via its anti-inflammatory property.

Phase:

N/A

Details

Lead Sponsor:

The University of Hong Kong

Treatments:

Pioglitazone